NYSE:CTLT - Catalent Stock Price, Price Target & More

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Catalent (NYSE:CTLT) issued its earnings results on Tuesday, May, 1st. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.06. The company had revenue of $627.90 million for the quarter, compared to analyst estimates of $610.47 million. Catalent had a net margin of 2.62% and a return on equity of 21.76%. The company's revenue for the quarter was up 17.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.38 EPS. View Catalent's Earnings History.

Catalent is scheduled to release their next quarterly earnings announcement on Monday, August, 27th 2018. View Earnings Estimates for Catalent.

Catalent updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided EPS guidance of $1.57-$1.74 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.67. The company issued revenue guidance of $2.42-$2.48 billion, compared to the consensus revenue estimate of $2.45 billion.

14 Wall Street analysts have issued 1-year price objectives for Catalent's shares. Their predictions range from $38.00 to $50.00. On average, they expect Catalent's stock price to reach $45.8182 in the next twelve months. View Analyst Ratings for Catalent.

Some companies that are related to Catalent include Mylan (MYL), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Nektar Therapeutics (NKTR), Sarepta Therapeutics (SRPT), Genmab A/S (GNMSF), BeiGene (BGNE), Valeant Pharmaceuticals Intl (VRX) and Alkermes (ALKS).

News coverage about CTLT stock has been trending somewhat positive recently, according to Accern. The research group rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Catalent earned a coverage optimism score of 0.03 on Accern's scale. They also gave headlines about the company an impact score of 46.17 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Catalent's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.45%), JPMorgan Chase & Co. (3.21%), Champlain Investment Partners LLC (2.72%), American Century Companies Inc. (2.15%), Earnest Partners LLC (1.90%) and Northern Trust Corp (1.52%). Company insiders that own Catalent stock include Blackstone Management Associat, Christine Dolan, Donald E Morel, Jr, John R Chiminski, Sharon Johnson, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.

CTLT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, BNP Paribas Arbitrage SA, Hood River Capital Management LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co., Loomis Sayles & Co. L P and Carillon Tower Advisers Inc.. Company insiders that have sold Catalent company stock in the last year include Christine Dolan, John R Chiminski and William Downie. View Insider Buying and Selling for Catalent.

CTLT stock was purchased by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, Wells Fargo & Company MN, Prudential Financial Inc., GW&K Investment Management LLC, Impax Asset Management LLC, American Century Companies Inc., Segall Bryant & Hamill LLC and Mackay Shields LLC. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CTLT stock can currently be purchased for approximately $42.52.

Catalent has a market capitalization of $5.58 billion and generates $2.08 billion in revenue each year. The company earns $109.80 million in net income (profit) each year or $1.35 on an earnings per share basis. Catalent employs 10,800 workers across the globe.

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]